周一夜盘，生物制药公司伊克力西斯（Exelixis Inc，股票代码：EXEL）股价大幅下跌10.77%，主要原因是该公司公布的季度业绩未能达到市场预期。
根据伊克力西斯发布的最新财报，截至6月30日的季度调整后每股收益为0.65美元，虽然高于分析师平均预期的0.56美元，但低于去年同期的0.77美元。更令投资者失望的是，公司季度营收为5.6826亿美元，同比下降10.8%，且未达到分析师预期的5.7445亿美元。
尽管伊克力西斯本季度净收入达到1.8485亿美元，但收入和利润的双重下滑显然打击了投资者信心。值得注意的是，该公司股价今年迄今为止已上涨36.9%，此次业绩不佳可能引发了部分投资者的获利了结。分析师目前对该公司股票的平均评级仍为"买入"，12个月目标价中位数为46.00美元，略高于其上次收盘价。然而，考虑到本次业绩表现，未来可能面临评级调整的压力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.